Last reviewed · How we verify
Campath
At a glance
| Generic name | Campath |
|---|---|
| Also known as | Alemtuzumab, Nonmeylablative Stem Cell Transplant, Mini Transplant, alemtuzumab, Campath-1H |
| Sponsor | National Heart, Lung, and Blood Institute (NHLBI) |
| Target | CAMPATH-1 antigen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Conditioning treatment prior to allogeneic haematopoietic stem cell transplant
- Recurrent chronic lymphocytic leukemia
- Refractory chronic lymphocytic leukemia
- Relapsing remitting multiple sclerosis
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Infusion-related reactions
- Lymphopenia
- CMV infection
- Nausea
- Pyrexia
- Chills
- Emesis
- Diarrhea
- Insomnia
Serious adverse events
- Neutropenia (Grade 3/4)
- Thrombocytopenia (Grade 3/4)
- Anemia (Grade 3/4)
- Infusion-related reactions (Grade 3/4)
- Lymphopenia (severe)
- CMV viremia/infection
- Autoimmune thrombocytopenia
- Autoimmune thrombocytopenia with fatality
Key clinical trials
- Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita (PHASE2)
- Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study (PHASE1, PHASE2)
- Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists (PHASE1, PHASE2)
- Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases (PHASE1, PHASE2)
- Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide (EARLY_PHASE1)
- Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia (PHASE1, PHASE2)
- Allo HSCT for High Risk Hemoglobinopathies (PHASE2)
- Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Campath CI brief — competitive landscape report
- Campath updates RSS · CI watch RSS
- National Heart, Lung, and Blood Institute (NHLBI) portfolio CI